uniQure Announces Confidential Submission of Draft Registration Statement for Initial Public Offering

AMSTERDAM, The Netherlands, Nov. 11, 2013 (GLOBE NEWSWIRE) -- uniQure B.V., a leader in human gene therapy, today announced that it has confidentially submitted a registration statement on Form F-1 to the U.S. Securities and Exchange Commission ("SEC") relating to a possible initial public offering of its ordinary shares. The number of ordinary shares to be offered and the price range for the offering have not yet been determined.

Help employers find you! Check out all the jobs and post your resume.